Could a pill replace eye injections for Diabetes-Related vision loss?

NCT ID NCT07458061

Recruiting now Disease control Sponsor: Dr. Bryan Strelow Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing an oral drug called Kamuvudine-9 (K9) in 10 adults with diabetic macular edema, a condition that causes vision loss. The study aims to see if K9 is safe and whether it improves vision compared to a placebo. Participants will take either K9 or placebo tablets twice a day, and researchers will monitor side effects and changes in eyesight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Kamuvudine-9 (K9)
What this could lead to: If it works, this could point toward a new oral treatment for diabetic macular edema, potentially reducing the need for eye injections.
What could go wrong: This is a very early Phase 1/2 trial with only 10 participants, so results may not apply broadly. The drug may prove unsafe or no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC MACULAR EDEMA

Contacts and locations

Locations

Vistar Eye Center
RECRUITING

Roanoke, Virginia, 24019, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.